Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > August 3, 2022
Daily News
August 3, 2022
- AstraZeneca, Tech Nation Link Arms to Help Startups Foray into Japan, UK
August 3, 2022
- 7 Japan Scientific Societies Issue Proposal on Development of Vaccines, Anti-Infectives
August 3, 2022
- Astellas Taps Ex-AstraZeneca Exec Taniguchi as New CMO
August 3, 2022
- Sawai Grabs Japan Rights to CureApp’s NASH Therapeutic App
August 3, 2022
- Sosei, AbbVie Expand Collaboration into Neurological Arena
August 3, 2022
- Ayumi to Boost Calonal Output to 2.88 Billion Tablets, Still August Shortage Likely
August 3, 2022
- Chuikyo Will Consider Any Proposals of New Panel on Drug Pricing: Pharma Management Director
August 3, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…